Pharsight

Drug Patents owned by Covis

1. List of Alvesco drug patents

ALVESCO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(4 years from now)

Do you want to check out ALVESCO patents from before 2022?

Drugs and Companies using CICLESONIDE ingredient

Market Authorisation Date: 10 January, 2008

Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

ALVESCO family patents

6

United States

2

Japan

2

European Union

1

Croatia

1

Poland

1

Spain

1

Cyprus

1

Canada

1

Portugal

1

Denmark

1

Australia

1

Slovenia

2. List of Feraheme drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6599498 COVIS Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
Jun, 2023

(a month from now)

Do you want to check out FERAHEME patents from before 2022?

Drugs and Companies using FERUMOXYTOL ingredient

Market Authorisation Date: 30 June, 2009

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of FERAHEME before it's patent expiration?
More Information on Dosage

3. List of Makena drug patents

MAKENA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446441 COVIS Prefilled syringe injector
Jan, 2026

(2 years from now)

US9533102 COVIS Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US9180259 COVIS Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US8562564 COVIS Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US9629959 COVIS Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US8021335 COVIS Prefilled syringe jet injector
Oct, 2026

(3 years from now)

US11446440 COVIS Needle assisted injection device having reduced trigger force
Aug, 2031

(8 years from now)

US9789257 COVIS Needle assisted injection device having reduced trigger force
Feb, 2034

(10 years from now)

US11154562 COVIS Methods of reducing risk of preterm birth
May, 2036

(12 years from now)

US11304962 COVIS Methods of reducing risk of preterm birth
May, 2036

(12 years from now)

US9844558 COVIS Methods of reducing risk of preterm birth
May, 2036

(12 years from now)

US10471075 COVIS Methods of reducing risk of preterm birth
May, 2036

(12 years from now)

Do you want to check out MAKENA patents from before 2022?

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Market Authorisation Date: 03 February, 2011

Treatment: Reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

How can I launch a generic of MAKENA before it's patent expiration?
More Information on Dosage

MAKENA family patents

52

United States

7

Japan

6

European Union

3

Korea, Republic of

3

Spain

3

Canada

2

China

2

Portugal

2

Denmark

1

Israel

1

Brazil

1

Australia

1

Hungary

4. List of Omnaris drug patents

OMNARIS's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(4 years from now)

Do you want to check out OMNARIS patents from before 2022?

Drugs and Companies using CICLESONIDE ingredient

Market Authorisation Date: 20 October, 2006

Treatment: Treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment of nasal symptoms associated w perennial allergic rhinitis in adults a...

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of OMNARIS before it's patent expiration?
More Information on Dosage

OMNARIS family patents

6

United States

2

Japan

2

European Union

1

Croatia

1

Poland

1

Spain

1

Cyprus

1

Canada

1

Portugal

1

Denmark

1

Australia

1

Slovenia

5. List of Zetonna drug patents

ZETONNA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(4 years from now)

Do you want to check out ZETONNA patents from before 2022?

Drugs and Companies using CICLESONIDE ingredient

Market Authorisation Date: 20 January, 2012

Treatment: Treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child

Dosage: AEROSOL, METERED;NASAL

More Information on Dosage

ZETONNA family patents

6

United States

2

Japan

2

European Union

1

Croatia

1

Poland

1

Spain

1

Cyprus

1

Canada

1

Portugal

1

Denmark

1

Australia

1

Slovenia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic